The FDA granted accelerated approval to the antibody–drug conjugate trastuzumab deruxtecan for the treatment of patients with non–small cell lung cancer bearing oncogenic HER2 mutations who have experienced disease progression following systemic platinum-based therapy.

You do not currently have access to this content.